- Home
- XLO
as 11-25-2025 12:18pm EST
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 41.8M | IPO Year: | 2021 |
| Target Price: | $2.00 | AVG Volume (30 days): | 996.7K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $1.70 | Next Earning Date: | 11-13-2025 |
| Revenue: | $31,804,000 | Revenue Growth: | 588.40% |
| Revenue Growth (this year): | 519.7% | Revenue Growth (next year): | 44.57% |
Latest Xilio Therapeutics Inc. News
XLO Breaking Stock News: Dive into XLO Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
Zacks
13 days ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
GlobeNewswire
18 days ago
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
GlobeNewswire
18 days ago
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
GlobeNewswire
22 days ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance
24 days ago
Wall Street says tokenization will change global markets. Gold is next.
Yahoo Finance Video
24 days ago
US negotiating power is strong across the globe, except in China
Benzinga
24 days ago
DeepSeek, Qwen AI Besting ChatGPT, Grok, Gemini In AI Crypto Trading Challenge
Compare XLO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XLO Xilio Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.